Publications by authors named "K Hasselmann"
Early clinical trial unit tumor board: a real-world experience in a national cancer network.
J Cancer Res Clin Oncol
November 2023
Purpose: Early clinical trials are the first step into clinical therapies for new drugs. Within the six Bavarian university-based hospitals (Augsburg, Erlangen, Regensburg, Munich (LMU and TU), Würzburg) we have enrolled a virtual network platform for patient discussion.
Methods: The virtual Early Clinical Trial Unit Tumor Board (ECTU Tumor Board) is a secured web-based meeting to evaluate early clinical trial options for patients, where representatives from local ECTUs participate.
Article Synopsis
- The study looks at how some cancer cells (mantle cell lymphoma) don't respond well to a drug called temsirolimus, which is supposed to help treat them.
- Researchers created a special type of these cancer cells that are resistant to temsirolimus to find out why the drug doesn't work.
- They found that a gene called MET is really important for making the cells resistant, and using temsirolimus together with another drug called crizotinib could help make the cancer cells more sensitive to treatment again.
Background: Targeted therapies have substantially improved survival in cancer patients with malignancies outside the brain. Whether in-depth analysis for molecular alterations may also offer therapeutic avenues in primary brain tumors remains unclear. We herein present our institutional experience for glioma patients discussed in our interdisciplinary (MTB) implemented at the Comprehensive Cancer Center Munich (LMU).
View Article and Find Full Text PDFCancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.
J Cancer Res Clin Oncol
September 2023
Purpose: For patients with cancer of unknown primary (CUP), treatment options are limited. Precision oncology, the interplay of comprehensive genomic profiling (CGP) and targeted therapies, aims to offer additional treatment options to patients with advanced and hard-to-treat cancers. We aimed to highlight the use of a molecular tumor board (MTB) in the therapeutic management of CUP patients.
View Article and Find Full Text PDFPurpose: In 2016, the University of Munich Molecular Tumor Board (MTB) was implemented to initiate a precision oncology program. This review of cases was conducted to assess clinical implications and functionality of the program, to identify current limitations and to inform future directions of these efforts.
Methods: Charts, molecular profiles, and tumor board decisions of the first 1000 consecutive cases (01/2016-03/2020) were reviewed.